Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics
Authors McConnell SA, Desai DN, Faldu SP, Hard ML, Wehr AY, Weiden PJ, von Moltke L
Received 6 June 2017
Accepted for publication 7 June 2017
Published 12 July 2017 Volume 2017:13 Pages 1815—1816
Checked for plagiarism Yes
Editor who approved publication: Dr Roger Pinder
Scott A McConnell,1 Dharmik N Desai,1 Sejal P Faldu,1 Marjie L Hard,2 Angela Y Wehr,3 Peter J Weiden,1 Lisa von Moltke3
1Medical Affairs, Alkermes, Inc., Waltham, MA, 2Nuventra Pharma Sciences, Durham, NC, 3Clinical Research, Alkermes, Inc., Waltham, MA, USA
The recent publication by Salzman et al1 compared pharmacokinetic (PK) data from population PK (popPK) models for two long-acting antipsychotic formulations: aripiprazole once-monthly 400 mg (AOM 400) and aripiprazole lauroxil (AL). We would like to address a few major concerns. The AL popPK model has been well described in a peer-reviewed publication.2 However, Salzman et al omitted publishing information regarding the development and validation of the AOM popPK model, including any critical discussion of the covariates, other key characteristics, assumptions and limitations of the AOM model. Thus, a reader cannot objectively assess the simulated values for AOM reported in the publication.
View the original paper by Salzman and colleagues.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]